Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21

Annels, Nicola; Simpson, Guy R.; Arif, Mehreen; Denyer, Mick; Iqbal, Attya; Mansfield, David; Sandhu, Sarbjinder; Melcher, Alan; Harrington, Kevin J.; Au, Gough G.; Grose, Mark; Shafren, Darren R.; Mostafid, Hugh; Pandha, Hardev

doi:10.1186/2051-1426-3-s2-p331

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has encouraged the design of clinical trials for tumor patients that are based on the simultaneous administration of tumor antigen-loaded DCs and MMC 119. Intracellular adhesion molecule-1 and decay accelerating factor, the viral entry receptors for Coxsackie virus A21, have been shown to be upregulated in the presence of MMC, leading to synergy between virus and drug 120. HSV-1,121–123 vaccinia,124 and adenovirus177 have all shown synergy with MMC, but these studies have not identified any immune-function mechanism.…”

Section: Combining Chemotherapeutic Drugs With Ov Therapymentioning

confidence: 99%

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Simpson¹,

Relph²,

Harrington³

et al. 2016

Self Cite

View full text Add to dashboard Cite

Oncolytic viruses are multifunctional anticancer agents with huge clinical potential, and have recently passed the randomized Phase III clinical trial hurdle. Both wild-type and engineered viruses have been selected for targeting of specific cancers, to elicit cytotoxicity, and also to generate antitumor immunity. Single-agent oncolytic virotherapy treatments have resulted in modest effects in the clinic. There is increasing interest in their combination with cytotoxic agents, radiotherapy and immune-checkpoint inhibitors. Similarly to oncolytic viruses, the benefits of chemotherapeutic agents may be that they induce systemic antitumor immunity through the induction of immunogenic cell death of cancer cells. Combining these two treatment modalities has to date resulted in significant potential in vitro and in vivo synergies through various mechanisms without any apparent additional toxicities. Chemotherapy has been and will continue to be integral to the management of advanced cancers. This review therefore focuses on the potential for a number of common cytotoxic agents to be combined with clinically relevant oncolytic viruses. In many cases, this combined approach has already advanced to the clinical trial arena.

show abstract

Section: Combining Chemotherapeutic Drugs With Ov Therapymentioning

confidence: 99%

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Simpson¹,

Relph²,

Harrington³

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The oncloytic coxsackievirus CA 21 target the Intercellular Adhesion Molecule I (ICAM-1) on tumour cells surface. It has already showed promising activity in melanoma as well as in non muscular invasive bladder cancer [42,43]. To date the safety of combination between pembrolizumab and CA21 in advanced or recurrent tumours is being evaluated in phase I clinical trial (NCT02043665).…”

Section: Immune-checkpoint Inhibitors and Oncolytic Virusesmentioning

confidence: 99%

Immune checkpoint inhibitors for metastatic bladder cancer

Massari

Nunno

Cubelli

et al. 2018

Cancer Treatment Reviews

View full text Add to dashboard Cite

Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.

show abstract

“…This Phase II trial reported that treatments were well tolerated and a specific antitumor immune response was noted in 16 patients’ pretransurethral resection of the bladder tumors. [ 43 ]…”

Section: Vaccinesmentioning

confidence: 99%

“…ALT-801 is a fusion protein (IL-2 and TCR) that recognizes surface antigens derived from p53 in vivo in p53+/HLA-A2+ tumor xenografts. [ 43 ] A current Phase Ib/II trial is investigating safety, tolerability, and cancer recurrence rates up to 13 weeks in patients with high-grade Ta, T1, or Tis NMIBC treated with ALT-801 and IV gemcitabine.…”

Section: Vaccinesmentioning

confidence: 99%

New therapies in nonmuscle invasive bladder cancer treatment

et al. 2018

View full text Add to dashboard Cite

Introduction:Nonmuscle invasive bladder cancer (NMIBC) remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. Recent technological and biological advances have led to the development of novel agents in NMIBC therapy.Methods:We reviewed existing literature as well as currently active and recently completed clinical trials in NMIBC by querying PubMed.gov and clinicaltrials.gov.Results:A wide variety of new therapies in NMIBC treatment are currently being developed, utilizing recent developments in the understanding of immune therapies and cancer biology.Conclusion:The ongoing efforts to develop new therapeutic approaches for NMIBC look very promising and are continuing to evolve.

show abstract

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21

Cited by 6 publications

References 0 publications

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Immune checkpoint inhibitors for metastatic bladder cancer

New therapies in nonmuscle invasive bladder cancer treatment

Contact Info

Product

Resources

About